Company Analysis Five Prime Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (822.33%) is higher than the sector average (-49.04%).
Disadvantages
- Price (37.94 $) is higher than fair price (22.67 $)
- Dividends (0%) are below the sector average (0.5339%).
- The company's current efficiency (ROE=-40.58%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Five Prime Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.2% | -35.1% | 0.4% |
| 90 days | 116.6% | -48% | 7.4% |
| 1 year | 822.3% | -49% | 17.3% |
FPRX vs Sector: Five Prime Therapeutics, Inc. has outperformed the "Healthcare" sector by 871.37% over the past year.
FPRX vs Market: Five Prime Therapeutics, Inc. has outperformed the market by 805% over the past year.
Slightly volatile price: FPRX is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: FPRX with weekly volatility of 15.81% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (37.94 $) is higher than the fair price (22.67 $).
Price is higher than fair: The current price (37.94 $) is 40.2% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (0) is higher than that of the sector as a whole (-274.25).
P/E vs Market: The company's P/E (0) is higher than that of the market as a whole (-80.5).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (6.7) is lower than that of the sector as a whole (256.7).
P/BV vs Market: The company's P/BV (6.7) is lower than that of the market as a whole (51.89).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (106.2) is higher than that of the sector as a whole (56.99).
P/S vs Market: The company's P/S indicator (106.2) is lower than that of the market as a whole (137.42).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-20.45) is lower than that of the sector as a whole (12.51).
EV/Ebitda vs Market: The company's EV/Ebitda (-20.45) is higher than that of the market as a whole (-47.95).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.73%).
6.4. ROE
ROE vs Sector: The company's ROE (-40.58%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (-40.58%) is lower than that of the market as a whole (-10.25%).
6.6. ROA
ROA vs Sector: The company's ROA (-30.35%) is lower than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (-30.35%) is lower than that of the market as a whole (39.65%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-32.9%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-32.9%) is lower than that of the market as a whole (8.73%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5339%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
